Sjögren's disease

News

A young woman covers her face with her hands

Amgen's Horizon buyout delivers Sjögren's disease win

Amgen's anti-CD40L drug dazodalibep has shown efficacy in Sjögren's in a phase 3 trial, raising hopes for a disease-modifying drug for the disorder.

News

Spero snaps up Innovent immunology drug in strategic pivot

Spero has licensed rights to an anti-CD40L antibody developed by China's Innovent, in a $1.1bn deal that signals a shift away from antimicrobial R&D.

News

More good news in Sjogren's as RemeGen trial delivers

A second new drug, RemeGen's telitacicept, has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week.

News

woman drinking from large plastic water bottle

MorphoSys takeover delivers phase 3 win for Novartis

A drug for autoimmune disease Sjögren's syndrome, claimed by Novartis when it bought MorphoSys, could soon be filed for approval.

News

J&J's nipocalimab fast-tracked for Sjogren's disease

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjogren's disease.

News

J&J’s nipocalimab raises hope for Sjogren’s patients

Johnson & Johnson’s ‘Swiss army knife’ for autoimmune diseases – FcRn inhibitor nipocalimab – has shown efficacy in Sjogren’s disease (SjD), an autoimmune condition that affects million

Amgen's Horizon buyout delivers Sjögren's disease win

Spero snaps up Innovent immunology drug in strategic pivot

More good news in Sjogren's as RemeGen trial delivers

MorphoSys takeover delivers phase 3 win for Novartis

J&J's nipocalimab fast-tracked for Sjogren's disease

J&J’s nipocalimab raises hope for Sjogren’s patients

Roche's IgAN hopeful sefaxersen passes phase 3 test

Discover a new era of healthcare panel engagement: Grounded ...

Sjögren's disease

Editor's Picks